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Abstract 
The recent outbreaks of H5N1 avian and H1N1 swine-origin influenza viruses highlight the urgent need for vaccine strategies 
able to confer broad host immunity against both seasonal and pandemic strains of influenza. As the lung mucosa is the first 
barrier against pulmonary influenza infection, an effective influenza vaccine strategy should elicit anti-viral immune responses in 
the respiratory tract where they may afford better protection. As a safe alternative to live attenuated vaccines, we evaluated the 
immunogenicity of gene gun-based immunization using a tetravalent DNA vaccine encoding the HA genes from three seasonal 
flu strains (H1, H3, and B) and a H5N1 pandemic strain. Vaccinated mice were found to exhibit high titers of serum antibodies 
specific for each of the encoded HA antigens, as well as cross-reactivity to drifted strains of virus. Importantly, significant levels 
of HA-specific mucosal antibodies were also detected in the lung airways of vaccinated mice. Consistent with the belief that 
immune responses against conserved regions of the virus may provide cross-protection against divergent strains of influenza, we 
also evaluated the immunogenicity of particle-mediated DNA vaccines encoding the highly conserved viral nucleoprotein (NP). 
Mice immunized with a DNA vaccine encoding a consensus NP sequence derived from circulating strains of virus exhibited 
robust NP-specific CD8 T cell responses in both spleen and lung tissue. Together, these results demonstrate the ability of skin-
delivered particle-mediated DNA vaccines to elicit strong systemic and mucosal immune responses against both variable and 
conserved influenza antigens and support the concept that particle-mediated DNA vaccines may offer an effective strategy to 
improve protection against seasonal and pandemic influenza. 
© 2010 Published by Elsevier Ltd. 
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1. Introduction 
The recent H5N1 avian and H1N1 swine-origin influenza virus outbreaks reaffirm the continuing threat of a 
worldwide influenza outbreak. When the next influenza pandemic occurs, the preparedness of the U.S. healthcare 
system to handle the levels of morbidity and mortality experienced with past pandemics is uncertain and existing 
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influenza vaccine strategies may be unable to meet the vaccination needs in advance of a rapidly advancing 
pandemic. Antibody responses elicited by conventional killed influenza vaccines (TIV) are capable of conferring 
host protection against homologous viruses, but these responses are less effective against variant viruses and provide 
little or no protection against genetically-drifted viruses. Furthermore, the timeframe for the manufacture and 
distribution of killed influenza vaccines (~6-8 months) will prevent these vaccines from being available before a 
pandemic spreads worldwide [1, 2]. New live attenuated vaccine strategies (LAIV) offer the promise of 
heterologous protection against drifted strains of virus, but these vaccines still suffer from long production and 
delivery timeframes [3]. Therefore, due to the short time-frame between identification of a pandemic strain and need 
for vaccination, the challenge is to develop new vaccine strategies with better "real-time" access and the ability to 
provide broad-spectrum protection against divergent strains of influenza virus. 
 
DNA vaccines possess a number of characteristics that give them a theoretic advantage over current influenza 
vaccine strategies to meet the threat of an influenza pandemic. First, DNA vaccines can be rapidly constructed, 
manufactured, and distributed soon after the identification of the newly emerging strain. Second, influenza DNA 
vaccines have conferred host protection against homologous and drifted strains of influenza virus. DNA vaccines 
encoding the hemagglutinin (HA) gene of various subtypes of virus have induced protective neutralizing antibody 
responses in mice, pigs, chickens, and ferrets [4]. In many of these studies, HA DNA vaccines were found to confer 
better protection against homologous viruses than the conventional killed vaccine [5-7]. In addition, DNA vaccines 
encoding highly conserved internal viral proteins such as nucleoprotein (NP) and matrix have been shown to provide 
cross-strain protection in animal studies, with protection correlated to the induction of T cell responses against the 
internal proteins [8-10]. 
 
Particle mediated epidermal delivery (PMED), also described as the gene gun, involves the use of a needle-free 
device to deliver DNA vaccines coated onto 1-3 μm gold beads into the skin epidermis. PMED immunization differs 
from parenteral injection of DNA in that plasmid is injected directly into the intracellular environment of both non-
professional APCs (i.e. keratinocytes) and professional antigen presenting cells (i.e. Langerhans cells) residing in 
the epidermis [11, 12]. PMED influenza DNA vaccines have been extensively studied in relevant animal models and 
been shown to elicit protective antibody and cytotoxic T cell responses against homologous and drifted strains of 
influenza A virus [4]. PMED has consistently demonstrated an ability to elicit significant antibody and T cell 
responses without the use of adjuvants or viral vector boosting in a number of clinical studies [13-15], and is the 
only DNA vaccine delivery method shown to induce protective levels of influenza-specific antibody in a human 
clinical trial [16]. Notably, PMED-based DNA vaccination differs from other DNA vaccine delivery methods in its 
apparent ability to elicit mucosal immunity, an effect likely explained by the notion that the skin epidermis is 
capable of priming both systemic and mucosal immune responses [17-19]. Mucosal immune responses induced in 
the gut and lungs following PMED DNA vaccination have been shown to provide strong protection against mucosal 
AIDS and influenza viral challenges [20-22]. In summary, these data support the notion that PMED represents an 
attractive vaccine strategy against seasonal and pandemic influenza. 
 
An effective PMED DNA vaccine strategy against seasonal and pandemic influenza viruses will require the 
construction of a multivalent vaccine capable of providing broad protection against multiple viral types and 
subtypes. We hypothesize that a PMED DNA vaccine capable of inducing antibody responses against HA antigens 
of multiple viral strains, in addition to T cell responses against highly conserved regions of the viral NP will provide 
the broad spectrum of immunity required to protect against an influenza pandemic. In this study, we evaluated the 
immunogenicity of tetravalent DNA vaccines expressing HA antigens (H1, H3, B, and H5), as well as DNA 
vaccines encoding a consensus influenza A NP gene sequence. We provide evidence that tetravalent HA DNA 
vaccine immunogenicity is highly impacted by the manner in which the HA genes are expressed on the plasmid 
(single vs. multiple) and how the DNA vaccine is delivered (single vs. same bead). We also show that our PMED 
NP DNA vaccine is capable of eliciting robust NP-specific CD8 T cell responses in both the periphery and lung 
mucosa. 
 
2. Materials and Methods 
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2.1 Mice and sample collection 
Adult (6-8 week old) female BALB/c mice were purchased from Taconic (Germantown, NY) and maintained 
under specific pathogen–free conditions in the Albany Medical College’s Animal Resources Facility. All animal 
procedures were approved by Albany Medical College’s Institutional Animal Care and Use Committee. Blood 
samples were collected from mice at the indicated times post-vaccination via retro-orbital bleeding and sera isolated 
using Microtainer® serum separator tubes (BD Diagnostics, Franklin Lakes, NJ). Bronchoalveolar lavage fluid 
(BALF) was collected at necropsy by instilling and aspirating 1.0 ml of sterile PBS through the trachea and into the 
lungs. Lymphocytes were collected from the spleens and lungs of mice as described [23]. Lung tissue was digested 
using Type IV Collagenase (Sigma, St. Louis, MO) and lymphocytes were then isolated over an 80/40% Percoll 
gradient (GE Healthcare, Piscataway, NJ).  
 
2.2 Influenza DNA vaccines 
The protein sequences for the hemagglutinin (HA) antigens from influenza A/New Caledonia/20/99 (H1N1), 
A/Panama/2007/99 (H3N2), B/Jiangsu/10/2003, and A/Vietnam/1203/04 (H5N1) were submitted to GeneArt 
(Regensburg, Germany) for the design of optimized coding sequences using the GeneOptimizer® software. Each 
HA gene was inserted into a modified clinical-grade plasmid (pPJV7563; PowderMed Ltd., Oxford, UK; [19]) as 
either a monovalent or multivalent expression cassettes (Table 1). Resulting plasmids were analyzed for HA antigen 
expression by immunofluorescent labeling of transfected cells with specific HA antibodies as described [22]. 
 
A consensus sequence for the influenza A nucleoprotein (NP) was created from alignments performed using the 
amino acid sequences for the full-length NP proteins from the A/New Caledonia/20/99, A/Panama/2007/1999, and 
A/Vietnam/1194/2004 viral strains retrieved from the NCBI Influenza Virus Resource website 
(http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html).  The consensus sequence (NPcon) was submitted to 
GeneArt for optimization of coding sequences using the GeneOptimizer® software and the resulting gene sequence 
was inserted into the pPJV7563 plasmid. The resulting plasmid was analyzed for expression of the full-length 
NPcon by Western blot analyses of transfected cells with an influenza A NP-specific monoclonal antibody (clone 
IC5-1B7; NIH Biodefense and Emerging Infections Research Resources Repository, NIAID). 
 
 
Table 1: Influenza HA PMED DNA vaccine formulations tested 
Monovalent HA DNA vaccine formulations 
PML-H1 HA from A/New Caledonia/20/99 
PML-H3 HA from A/Panama/2007/99 
PML-B HA from B/Jiangsu//10/20 
PML-H5 HA from A/Vietnam/1203/2004 
Bi- and Trivalent HA DNA vaccine formulations
PML-H1/B Bivalent;  H1 and B HA genes on a single plasmid 
PML-H3/H5 Bivalent;H3 and H5 HA genes on a single plasmid  
PML-H1/H3/B Trivalent; H1, H3, and B HA genes on a single plasmid 
PML-H1+H3+B Trivalent; H1, H3, and B HA monovalent plasmids loaded onto individual beads 
Tetravalent HA DNA vaccine formulations 
PML-H1/H3/B/H5 All 4 HA genes expressed on a single plasmid 
PML-H1/H3/B +H5 One trivalent HA plasmid and one monovalent HA plasmid loaded onto 
individual beads 
PML-H1/B + H3/H5 Two bivalent HA plasmids loaded onto individual beads 
PML-H1+H3+B+H5 All 4 monovalent HA plasmids loaded onto individual beads 
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2.3 DNA vaccinations 
Plasmid DNA was precipitated onto 1- to 3-ȝm gold particles as previously described [24] at a rate of 2.0 ȝg 
DNA/mg of gold. For vaccine formulations containing a single plasmid, individual plasmids were coated 1.0 ȝg of 
each plasmid on the same gold beads. For those DNA vaccine formulations containing multiple plasmids, each 
plasmid was coated onto separate gold particles that were then mixed at equal ratios prior to immunization. 
Abdominal fur was clipped from mice and DNA-coated gold particles were accelerated into the abdominal skin of 
mice by particle mediated epidermal delivery (PMED) using an XR-1 research delivery device (PowderJect 
Vaccines, Inc., Madison, WI). DNA/gold was delivered at a helium pressure of 400 lb/in.2 (psi) for mice. Each 
delivery consisted of 0.5 mg of gold and 1.0 ȝg of DNA. A dose of 2 ȝg of DNA per immunization was achieved by 
administering DNA into 2 sites in mice. Consecutive DNA immunizations were spaced 4 weeks apart. 
 
2.4 Detection of antigen-specific antibody responses 
HA-specific IgG antibodies in sera and BALF from vaccinated mice were detected using a standard direct 
ELISA. Briefly, serial dilutions of sample were added to EIA/RIA plates (Corning, Corning, NY) previously coated 
with 31 ng/well of purified recombinant H1, H3, B, or H5 HA proteins (Protein Sciences, Meriden, CT). Detection 
was accomplished using HRP-conjugated goat anti-mouse IgG antibodies and TMB liquid substrate (both Sigma). 
Data are expressed as the highest reciprocal dilution giving an OD450 value 3 times greater than the OD450 obtained 
for negative control sera. 
 
The presence of influenza A/New Caledonia/20/99 reactive antibody in RDE (Accurate Chemical & Scientific 
Corp., Westbury, NY) treated sera samples were analyzed for using a hemagglutination inhibition (HI) assay as 
described [25]. Briefly, two-fold serial dilutions of RDE-treated sera were incubated with four hemagglutination 
units of influenza A/New Caledonia/20/99 virus followed by the addition of turkey erythrocytes. Serum HAI titers 
are reported from the average of duplicate tests as the reciprocal dilution of serum found to inhibit hemagglutination. 
A titer of 5 was assigned to those serum samples that failed to inhibit hemagglutination at the starting dilution of 
1/10. 
 
2.5 IFN-J ELISpot assay 
The number of IFN-J secreting T cells derived from spleens and lungs of vaccinated mice was determined using a 
standard ELISpot assay [26]. Briefly, lymphocytes were stimulated a peptide corresponding to the amino acid 
residues 147-155 of the influenza A NP protein (TYQRTRALV; 10 ȝg/ml final). This sequence is considered to be 
the dominant CD8 T cell epitope recognized by BALB/c mice and is common to a number of different influenza A 
virus strains [27, 28]. Concanavalin A (Sigma) was used for positive control wells (5 ȝg/ml final) and media 
supplemented with 80% DMSO for negative control wells. Spot forming cells (SFC) were enumerated using an 
ImmunoSpot® Analyzer with CTL ImmunoSpot® Professional Software (Cellular Technology Ltd., Shaker 
Heights, OH). Results are expressed as the mean number of SFC in replicate wells containing peptide minus the 
mean number of SFC in wells containing media/80% DMSO. Responses significantly higher than background levels 
(twice the number of SFCs enumerated in wells containing untreated cells plus 10 spots) were considered positive. 
 
3. Results 
3.1. Impact of vaccine formulation on tetravalent influenza HA PMED DNA vaccine immunogenicity 
An effective PMED DNA vaccine strategy against influenza virus infection will require the construction of a 
multivalent vaccine capable of providing adequate protection against circulating strains of virus. Theoretically, 
equivalent expression of each plasmid would promote immunogenicity against each of the encoded viral antigens. 
However, co-delivery of multiple plasmids on the same particle can result in antigenic competition, with reduced 
immunogenicity and/or immunodominance of one or more of the antigens encoded by the multivalent vaccine [29]. 
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Figure 1: HA-specific serum IgG responses post-vaccination. ELISA assays were performed on sera collected 4 
weeks post-boost to measure the titers of antibody specific for the individual HA antigens.  (A) Mice immunized 
with mono-, bi, and trivalent HA PMED DNA vaccines. (B) Mice immunized with tetravalent HA PMED DNA 
vaccines. Data shown are mean titers (± StDev) calculated for each vaccine group (n=5).  
Precipitating individual plasmids onto separate beads for delivery into separate cells is one method of avoiding 
antigenic competition when formulating multivalent PMED DNA vaccines. To determine whether expression of 
multiple HA genes on a single plasmid influences the relative immunogenicity of each antigen, we constructed DNA 
vaccines encoding the HA genes from A/New Caledonia/20/99 (H1), A/Panama/2007/99 (H3), B/Jiangsu/10/2003, 
and A/Vietnam/1203/2004 (H5). A total of 12 HA DNA vaccines were constructed, expressing one, two, three, or 
all four HA antigens (Table I), and PMED was used to deliver each HA DNA vaccine to BALB/c mice. Mice 
received 2 doses of DNA spaced 4 weeks apart (2 Pg of DNA per immunization). Blood and BALF were collected 4 
weeks after the last dose to analyze serum and mucosal antibody responses. 
 
     As shown in Figure 1A, mice immunized with the monovalent influenza HA PMED DNA vaccine formulations 
exhibited high titers of serum IgG specific for the encoded HA antigen, confirming the immune potency of the 4 
individual HA antigens. Mice vaccinated with the bi- and trivalent HA DNA vaccine formulations also presented 
with high titers of serum IgG specific for each of the encoded HA antigens. Importantly, the serum antibody titer 
specific for each respective HA elicited in mice vaccinated with the monovalent or bi/trivalent DNA vaccines were 
similar, indicating a lack of antigenic competition/interference with these vaccine formulations. Furthermore, mice 
given a DNA vaccine encoding the HA from A/Panama/2007/99 were found to possess serum antibodies cross-
reactive to the drifted A/Wisconsin/67/2005 strain of H3N2 virus (<90% sequence homology; data not shown). 
 
      We next examined the immune potency of the four individual HA genes as encoded by our four tetravalent HA 
DNA vaccine formulations. As shown in Figure 1B, all tetravalent HA DNA vaccine formulations tested were able 
to induce serum IgG responses against the four encoded HA antigens. However, the titers of HA-specific antibody 
measured between the tetravalent vaccine formulations were not equal. Compared to the other vaccine groups, mice 
vaccinated with the tetravalent DNA vaccine expressing all 4 HA genes on a single plasmid (PML-H1/H3/B/H5) 
exhibited significantly lower titers of serum IgG specific for 2 out of the 4 HA antigens. Mice in this vaccine group 
showed an approximate 2 log reduction in anti-H5 HA mean antibody titer and 1 log reduction in anti-B HA mean 
antibody titer. Similarly, mice vaccinated with a mixture of the trivalent H1/H3/B HA DNA vaccine and a separate 
monovalent H5 HA DNA vaccine exhibited a lower mean titer of serum IgG specific for the B HA antigen. These 
results suggest that antigenic competition/interference did occur in mice vaccinated with these two tetravalent HA 
DNA vaccine formulations, supporting the notion that the manner in which multiple HA antigens are expressed by 
PMED DNA vaccines can impact the relative immunogenicity of each encoded HA antigen.  
 
3.2 Tetravalent influenza HA PMED DNA vaccination elicits HA-specific mucosal antibodies in the lungs of mice 
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Figure 2: HA-specific mucosal IgG responses post-vaccination. ELISA assays were performed on BALF 
collected 4 weeks post-boost to measure the titers of mucosal antibody specific for the individual HA antigens.  
(A) H1N1 HA-specific mucosal IgG. (B) H3N2 HA-specific mucosal IgG. Data shown are mean titers (± StDev) 
calculated for each vaccine group (n=5). ND; not determined. 
     Mucosal immunity acquired by natural influenza virus infection has been shown to confer protection against 
subsequent exposure to both homologous and heterologous viruses [30]. This protection is mediated in part by the 
induction of mucosal antibody in the respiratory tract. Consistent with previous findings showing that PMED 
vaccination induces mucosal immunity, H1 and H3 HA-specific IgG were detected in BALF collected from mice 
vaccinated with the mono-, bi-, tri-, and tetravalent HA DNA vaccine formulations (Figure 2A and 2B). As 
observed with serum antibody, the specificity of mucosal IgG elicited in vaccinated mice was restricted to the HA 
antigens encoded by each of the vaccine formulations. Although evidence for antigenic competition was not as 
apparent in BALF samples as it was for serum samples, the two tetravalent HA DNA formulations found to elicit 
consistently high titers of HA-specific serum IgG (H1/B+H3/H5 and H1+H3+B+H5) were also found to elicit 
relatively high titers of HA-specific mucosal IgG. HA-specific mucosal IgA responses were not detected in any of 
the vaccine groups (data not shown). 
 
3.3 Identification of the optimal tetravalent HA PMED DNA formulation 
We next sought to directly compare the immunogenicity of the H1/B+H3/H5 and H1+H3+B+H5 tetravalent HA 
DNA vaccine formulations as a means to establish the optimal DNA vaccine formulation. Titers of HA-specific IgG 
were measured in the serum of vaccinated mice after the priming and boosting dose of DNA. As shown in Figure 
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Figure 3: Identification of optimal tetravalent HA PMED DNA vaccine formulation. Serum was collected 4 
weeks post-boost to measure the titers of H1 HA-specific IgG by ELISA (A) and A/New Caledonia/20/99 
(H1N1) neutralizing antibody by HI assay (B). Data shown are mean titers (± StDev) calculated for each vaccine 
group (n=5). 
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Figure 4: NP-specific CD8 T cell responses post-vaccination. Lymphocytes were isolated from the spleen and lungs 
of vaccinated mice 4 weeks post-boost and CD8 T cells specific for the dominant NP147-155 epitope were enumerated 
by IFN-J ELISpot assay. Data shown are the mean number of spot forming cells/106 cells (± StDev) calculated for 
each vaccine group (n=4). 
3A, mice vaccinated with the H1+H3+B+H5 tetravalent HA DNA vaccine showed a trend toward high titers of H1 
HA-specific serum IgG after priming (log10 mean titer of 2.92 vs. 2.17, respectively) and boosting (log10 mean titer 
of 3.94 vs. 3.07, respectively) as compared to the H1/B+H3/H5 vaccine group. We also tested for the presence of 
neutralizing antibodies in the sera of vaccinated mice following the boosting dose of DNA using a standard 
hemagglutinin inhibition assay (HI). As shown in Figure 3B, mice vaccinated with the H1+H3+B+H5 tetravalent 
HA DNA vaccine exhibited significantly higher titers of neutralizing serum antibodies against A/New 
Caledonia/20/99 flu virus (mean HI titer of 205 vs. 43, respectively). These data indicate that the H1+H3+B+H5 HA 
DNA vaccine formulation offers better immunogenicity than the other tetravalent DNA vaccine formulations and 
thus represents the optimal tetravalent PMED influenza HA DNA vaccine formulation. 
 
3.4 PMED DNA vaccine encoding conserved viral antigens elicits T cells in the lungs of vaccinated mice 
     T cell responses specific for conserved regions of the virus elicited following primary influenza virus infection or 
DNA vaccination have been shown to confer protection against subsequent infection by genetically drifted strains of 
virus (termed “heterologous immunity”) [8, 31, 32]. We therefore designed a construct expressing a consensus 
sequence for the conserved nucleoprotein (NPcon) from the individual NP sequences from A/New Caledonia/20/99, 
A/Panama/2007/1999, and A/Vietnam/1203/2004. BALB/c mice were immunized twice with the NPcon DNA 
vaccine at 4 week intervals (prime + boost) by PMED (2 Pg of DNA per dose). An ELISpot assay was used to 
enumerate T cells in the spleens and lungs of vaccinated animals specific for the dominant CD8 T cell epitope 
(NP147-155) recognized by BALB/c mice. As shown in Figure 4, measurable numbers of NP-specific CD8 T cells 
were detected in the spleens of mice primed and boosted with the NPcon PMED DNA vaccine (mean of 150 
SFC/106 spleen lymphocytes). Importantly, a NP-specific CD8 T cell response was also detected in the lungs of 
vaccinated mice (mean of 81 SFC/106 lung lymphocytes). These results confirm that ability of PMED DNA 
vaccination to induce T cell responses in not only the periphery, but also the lung mucosa, the first barrier against 
pulmonary influenza virus infection. 
 
 
4. Conclusions 
     In this study we assessed the immunogenicity of tetravalent influenza PMED DNA vaccines constructed to 
express HA antigens from 3 seasonal strains of influenza (H1, H2, and B) and one strain with pandemic potential 
(H5). We found that the manner in which multiple HA antigens are expressed by PMED DNA vaccines can impact 
the relative immunogenicity of each encoded HA antigen The tetravalent PMED HA DNA vaccine formulation 
found to consistently induce the best sera and mucosal antibody responses was the one where the individual 
monovalent HA plasmids were conjugated to separate beads (PML-H1+H3+B+H5). Conversely, reduced vaccine 
immunogenicity was observed with tetravalent DNA vaccines designed to express more than 2 HA genes on a single 
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plasmid. These findings are consistent with other studies involving multivalent DNA vaccines [29, 33] and can 
likely explained by the notion that separating expression of each antigen into different cells avoids intracellular 
competition between the DNA vaccine vectors. However, it may still be desirable to co-precipitate plasmids on the 
same gold bead when designing PMED DNA vaccines. Genetic adjuvants are often co-delivered with antigen-
encoding DNA vaccines into the same cell to enhance cell maturation, survival, and/or antigen 
processing/presentation. Several studies have shown this approach to significantly improve PMED DNA vaccine 
potency [4] and we are currently evaluating the impact of genetic adjuvant co-delivery on the immunogenicity of 
our tetravalent HA DNA vaccine. 
     Our studies also showed that a PMED DNA vaccine expressing a consensus sequence for the highly-conserved 
viral NP was able to induce peripheral and mucosal CD8 T cells specific for the dominant CTL epitope in BALB/c 
mice. [As CTL responses are critical for cross-protection, we are currently evaluating methods of augmenting the 
NP-specific CD8 T cell response induced by PMED NP DNA vaccination. Optimized peptide variants, also known 
as heteroclitic peptides, have been used to prime naïve CD8 T cells and induce a cross-reactive response against 
native proteins [34, 35]. Therefore, we are currently testing whether we can further enhance the CTL response 
against conserved regions of the viral NP by creating heteroclitic epitopes using a computer algorithm 
(EpitOptimizer) [36]. Also, following our recent observation that co-delivery of a plasmid encoding GM-CSF was 
able to enhance antigen-specific T cell responses in the blood and mucosa of PMED DNA vaccinated macaques 
[19], we are evaluating a variety of genetic adjuvants for their ability to boost NP-specific T cell responses. Our 
overall hypothesis is that by enhancing the magnitude and breadth of the NP-specific CD8 T cell response, 
vaccination will be better able to provide heterosubtypic immunity against genetically drifted strains of virus. 
      Mucosal immune responses can contribute to vaccine efficacy by blocking or limiting viral replication at the site 
of exposure [37]. Our results demonstrate that the ability of PMED DNA vaccination to induce both flu-specific 
antibody and T cell responses at mucosal surfaces where influenza infection takes place. As such, a PMED DNA 
vaccine constructed to induce antibody responses against HA and T cell responses against NP may provide superior 
protection against influenza virus infection compared to existing vaccine strategies. We are currently evaluating the 
immunogenicity and protective efficacy of our tetravalent HA and NP PMED DNA vaccines in ferret influenza 
infection model. Additionally, we are testing whether co-delivery of plasmids encoding the adjuvant heat-labile E. 
coli entertoxin (LT) can augment the ability of our PMED DNA vaccines to induce systemic and mucosal protective 
immune responses [26]. The ease at which DNA vaccines can be manufactured, along with the improved systemic 
and mucosal immunogenicity reported both here and in a recent study of ours [19], support the further development 
of particle-mediated DNA vaccines as a clinically-viable approach for improving vaccination against seasonal and 
pandemic influenza. 
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